Published by Josh White on 27th November 2019
(Sharecast News) - Hikma Pharmaceuticals has submitted its response to deficiencies in its abbreviated new drug application for a generic version of GlaxoSmithKline's 'Advair Diskus', or fluticasone propionate and salmeterol inhalation powder, to the US Food and Drug Administration (FDA), it announced on Wednesday.